By Finance Pulse in KeyInfo —

Guggenheim Upgrades Surrozen on Promising Liver Disease Data

Guggenheim upgrades Surrozen (SRZN) following promising Phase 1b trial results for its lead liver disease asset. Explore implications for SRZN stock.

A stylized representation of liver anatomy with vibrant colors, highlighting medical research and in
Guggenheim Upgrades Surrozen on Promising Liver Disease Data

Guggenheim upgraded Surrozen (SRZN) based on encouraging Phase 1b data for its lead asset in liver disease.

Source